Granules India Peer Comparison

NSE: GRANULES | BSE: 532482

₹836.65

₹4.35 (0.52%)

As on 28-Aug-2026IST

Market cap

₹20,739 Cr

Revenue (TTM)

₹5,632 Cr

P/E Ratio

31.3

P/B Ratio

4.2

Div. Yield

0.2 %

Edit

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	20,739	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	5,632	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	662.35	414.00	288.22	-371.81	387.35
Net Margin (%)	11.75	11.23	14.79	-3.93	26.01
RoE (%)	14.34	8.38	29.77	-3.85	25.18
Price to Earnings	31.31	78.49	103.71	--	69.57
Price-To-Book	4.23	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	5,365.64	3,373.00	1,753.96	8,869.08	1,006.88
Total Income	5,385.97	3,510.00	1,762.66	9,111.51	1,023.80
Total Expenditure	4,180.50	2,747.00	1,354.69	7,976.59	774.80
EBITDA	1,185.14	626.00	399.26	892.49	232.07
Depreciation	296.14	227.00	45.26	831.24	26.62
EBIT	889.00	399.00	354.00	61.25	205.45
Interest	114.35	213.00	42.17	340.80	6.22
Other Income	20.33	137.00	8.70	242.43	16.93
Exceptional Items	-10.00	-85.00	--	-196.14	--
Profit before Tax	784.98	238.00	320.53	-176.06	216.16
Provision for Tax	189.96	39.00	73.80	149.88	55.75
Profit after Tax	595.02	199.00	246.74	-325.94	160.42

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	5,085.00	4,940.00	1,288.82	8,162.62	1,309.63
Minority Interest	--	341.00	0.00	--	10.45
Non-Current Liabilities	479.08	1,235.00	189.02	4,529.41	26.93
Current Liabilities	2,092.03	1,622.00	835.87	4,874.74	202.25
Total Liabilities	7,682.91	8,578.00	2,326.71	17,723.32	1,549.26

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	3,888.46	5,441.00	631.90	10,258.66	757.63
Current Assets	3,767.65	2,606.00	1,681.81	7,308.11	791.64
Total Assets	7,682.91	8,578.00	2,326.71	17,723.32	1,549.26
Total Debt*	1,338.13	2,125.00	259.37	5,495.48	8.18
Net Current Assets	1,675.62	984.00	845.94	2,433.37	589.39
Contingent Liabilities	0.93	768.26	19.09	95.72	15.38

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	793.25	390.00	205.05	1,652.60	118.34
Cash Flow from Investing Activities	-773.21	-241.00	-409.72	-826.03	-223.94
Cash from Financing Activities	379.29	-54.00	283.07	-38.98	261.12
Net Cash Inflow / Outflow	399.33	95.00	78.39	787.59	155.52

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	15.74	6.79	29.22	1.24	20.14
ROE (%)	14.13	4.29	27.84	-4.04	16.19
ROA (%)	8.60	2.53	13.11	-1.98	12.13
EBIT Margin (%)	22.47	22.62	23.26	12.80	24.73
Net Margin (%)	11.05	5.67	14.00	-3.58	15.67
Cash Profit Margin (%)	8.89	10.98	7.71	4.80	18.58

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	19.73	11.99	36.57	-3.08	40.34
EBIT Growth (%)	25.81	67.69	52.29	-28.15	83.12
Net Profit Growth (%)	18.64	449.12	83.64	-457.66	229.35
EPS Growth (%)	16.13	553.20	71.44	-456.91	67.16
Book Value Growth (%)	27.49	13.47	144.31	0.33	94.96

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	25.87	89.54	51.69	0.00	62.97
Price / Book Value	3.26	3.87	10.14	2.24	15.26
Dividend Yield (%)	0.28	0.00	0.19	0.00	0.06
EV/EBITDA	13.09	27.45	31.05	19.72	79.31
Market Cap (₹ Cr)	15,391.88	19,071.62	12,753.19	18,108.89	19,988.69

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.28	0.43	0.21	0.68	0.01
Short term debt to equity ratio	0.20	0.09	0.05	0.09	0.01
Current Ratio	1.80	1.61	2.01	1.50	3.91
Quick Ratio	1.00	1.06	1.14	0.87	3.02
Interest Coverage	7.86	2.12	8.60	0.48	35.76

	Granules India	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	16.95	17.43	29.00	24.33	28.85
Asset Turnover	1.45	0.49	2.01	0.64	0.76
Receivable days	33.72	58.75	40.13	78.20	90.06
Inventory Days	54.92	75.82	60.29	93.30	61.02
Payable days	136.11	186.21	232.47	226.14	96.06
Cash Conversion Cycle	-47.47	-51.64	-132.04	-54.64	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.